ATTANA SECURES FINANCING FOR CONTINUED EXPANSION

Stockholm, May 2007 – Attana, a leading supplier of affordable label-free biosensor systems for real-time detection and analysis of molecular interactions, has secured financing for continued expansion. This is Attana’s significantly largest private placement to date and in addition to the existing majority owners, Carl Bennet AB and Östersjöstiftelsen, a new investor, Catella Healthcare has taken one third of the placement. The funds enable Attana to continue its aggressive expansion plans within marketing of existing products as well as new product development.

Annika Espander, CEO of Catella Healthcare comments, “We are excited about the capabilities of Attana, which we believe will result in the development of highly innovative and competitive products for which there is great industrial demand.”

“We are delighted in closing this round of financing as it confirms the long-term commitment of our existing owners and their strong belief in our continued success. And in attracting Catella Healthcare we have a new owner with thorough industry know-how in addition to further financial resources,” comments Dr. Teodor Aastrup, Attana’s CEO.

Attana develops and sells label-free biosensor systems for real-time detection and analysis of molecular interactions. Characterizing the kinetics and affinity of molecular interactions is crucial in understanding the function of antibodies, proteins, DNA, etc.. Attana’s A100® system enables studies of molecular interactions in real-time without the need of labels, resulting in faster and more cost effective research. Offering affordable access and high sensitivity, Attana's systems are employed at leading universities and biotech companies in a wide variety of research fields within the life sciences.

“This financing enables us to continue building our network of re-sellers and support services, increase our production capacity and aggressively invest in new product development,” concludes Dr.
Aastrup.

ABOUT Catella Healthcare
Catella Healthcare focuses on investments in the healthcare sector, notably life science, pharmaceutical development and medical technology. Catella Healthcare invests in listed and private companies, as well as offers strategic and financial advisory services.

ABOUT Carl Bennet AB
Carl Bennet AB, owned by Carl Bennet, is majority owner of the publicly traded companies Getinge AB (medtech) and Elanders AB (infomedia). Carl Bennet AB also owns the industrial group Lifco AB (100%).

ABOUT Östersjöstiftelsen
Östersjöstiftelsen (The Foundation for Baltic and East European Studies) was created by the Swedish government in 1994, with the aim of supporting research, training of doctoral students and the academic infrastructure at Södertörn University College (Stockholm, Sweden). At the beginning of 2007 the endowment's market value was €775 million.

ABOUT Attana
Based in Stockholm, Sweden, Attana AB was founded with the goal of becoming a world leader within sensor technologies for detecting, registering and measuring chemical and biochemical reactions, based on the Quartz Crystal Microbalance (QCM) technology. Today, Attana develops and sells the A100® biosensor along with consumables and associated services throughout Europe. Offering affordable access and high sensitivity, Attana's systems are employed at leading universities and biotech companies in a wide variety of research fields within life sciences.

ABOUT Technology
Quartz Crystal Microbalance (QCM) can be explained as a very sensitive scale or balance, which can measure atomic changes in mass. QCM uses the piezoelectric effect of quartz crystals, by applying an AC-potential to oscillate a quartz crystal. When atoms or molecules are added to, or removed from the surface, the change in the resonance frequency can be converted to a mass response. By attaching a specific molecule (the target) to the surface of the crystal and letting a sample flow over the surface, the target’s interaction with the sample can efficiently be studied. QCM can thereby be used to detect the presence of a substance or to characterise biochemical reactions, e.g. a drug candidate’s interaction with a protein.

For more information please contact Samir Christian Fostock +46 8 410 200 00 or visit www.attana.com